Daniel Stauder has given his Buy rating due to a combination of factors that highlight Artivion's strong financial performance and strategic growth opportunities. Primarily, the company demonstrated impressive revenue and EBITDA growth, with third-quarter sales exceeding expectations and adjusted EBITDA showing a notable increase. This financial outperformance was driven by significant growth in the aortic stent graft, On-X, and surgical sealants divisions. Furthermore, Stauder points to regulatory advancements and a promising pipeline as reasons to be optimistic about Artivion's future. The anticipated approval of BioGlue in China and progress in the U.S. IDE pivotal trial for the Nexus product are expected to contribute additional revenue streams. The company's robust EBITDA growth and potential for future margin expansion further support the positive outlook, aligning with a favorable valuation compared to peers.